Researchers at The Rockefeller University in New York City have determined how two medications used to treat cystic fibrosis…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward…
EnBiotix has raised $11 million in financing that will help fund clinical testing of ColiFin (inhaled colistimethate sodium) and…
An endoscopic sinus surgery (ESS) is best performed within a few years of a lung transplant in cystic…
People in the U.K. at highest risk of becoming seriously ill from COVID-19 — including those with cystic fibrosis (CF)…
Blocking the protein SGLT1, which regulates glucose uptake in cells, may be a useful in treating cystic fibrosis (CF), according…
Many women with cystic fibrosis (CF) wish to have biological children, but they often lack proper education and resources…
Epithelial cells collected from the nasal passages and grown in the lab under a specialized protocol could be a useful…
People with cystic fibrosis (CF) who score highly on measures of self-compassion tend also to report higher quality of…
Large-scale clinical trials and other research are “urgently required” to determine the best ways to manage the growing number of…